B. K. Wilder

Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype

The paper characterizes human antibodies against PfRH5, identifies key features of potent inhibitors, and demonstrates their prophylactic potential against malaria.

Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages

The paper isolates a human monoclonal antibody that targets Plasmodium vivax AMA1, blocking both pre-erythrocytic and blood stage infections.

Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine

This paper develops an accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine that provides sterile protection with a single day regimen.

Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and enhance protection of anti-CSP monoclonal antibodies

This study shows that anti-TRAP/SSP2 monoclonal antibodies inhibit sporozoite infection and enhance protection from CSP-based antibodies, suggesting a multivalent vaccine strategy could improve malaria vaccines.

Platelet Derived Growth Factor Receptor β (PDGFRβ) is a Host Receptor for the human malaria parasite adhesin TRAP

The paper identifies hPDGFRβ as a host receptor for the malaria parasite TRAP, showing its role in sporozoite motility and infection.

ELQ-331 as a prototype for extremely durable chemoprotection against malaria

This paper evaluates ELQ-331 as a long-acting injectable chemoprotective agent against malaria, showing it provides durable protection in mice for up to 4.5 months.